Stock page
Candid Therapeutics Inc (CDRX)
Candid Therapeutics Inc is focused on developing therapies for autoimmune diseases, including T-cell engager antibodies designed to redirect T-cells to target autoreactive B-cells. Its approach is based on ongoing research and current understanding of immunological mechanisms. The company's pipeline drug candidates include Cizutamig (BCMA/CD3), CND261 (CD20/CD3), CND319 (CD19/CD20/CD3), and CND460 (BCMA/CD19/CD3).
Quote snapshot
$0.00
Daily change: —
ExchangeNAS
Updated2026-05-09T04:34:00.837467Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|